Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Cinclus Pharma Holding AB ( (SE:CINPHA) ) is now available.
Cinclus Pharma reported a net sales increase to TSEK 9,744 for Q3 2025, but faced an operating loss of TSEK -44,122. Despite the financial losses, the company maintains a robust cash position with TSEK 540,220 in cash and equivalents, indicating a strong liquidity position to support ongoing operations and R&D efforts.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB operates in the pharmaceutical industry, focusing on the development of treatments for gastroesophageal reflux disease (GERD). The company is heavily invested in research and development, with a significant portion of its operating expenses dedicated to this area.
Average Trading Volume: 65,889
Technical Sentiment Signal: Hold
Current Market Cap: SEK828.4M
See more data about CINPHA stock on TipRanks’ Stock Analysis page.